Provention Bio, Inc.
(NASDAQ : PRVB)

( )
PRVB PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson
1.81%135.240.7%$973.72m
PFEPfizer Inc.
-0.41%36.350.9%$647.12m
MRKMerck & Co., Inc.
-0.68%84.460.7%$632.33m
ABBVAbbVie, Inc.
0.38%74.782.3%$562.65m
BMYBristol-Myers Squibb Company
-0.62%51.511.4%$504.14m
LLYEli Lilly and Company
-1.55%108.001.0%$303.30m
NVSNovartis AG Sponsored ADR
0.35%87.000.2%$150.48m
AZNAstraZeneca PLC Sponsored ADR
-0.95%43.791.2%$139.49m
GSKGlaxoSmithKline plc Sponsored ADR
0.04%42.290.3%$95.79m
SNYSanofi Sponsored ADR
0.40%45.740.2%$78.22m
NVONovo Nordisk A/S Sponsored ADR Class B
-0.36%52.280.1%$70.43m
LCILannett Company, Inc.
1.43%11.3835.6%$15.73m
AKTXAkari Therapeutics Plc Sponsored ADR
2.31%1.771.6%$0.52m
EPIXESSA Pharma Inc
-3.34%3.330.1%$0.09m

Company Profile

Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D); PRV-015 for the treatment of gluten-free diet non-responding celiac disease; PRV-6527 for Crohn's disease; PRV-300 for ulcerative colitis; PRV-3279 for the treatment of lupus; and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of T1D onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Lebanon, NJ.